MARKET

ONTX

ONTX

Onconova
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.5675
+0.0075
+1.34%
After Hours: 0.5675 0 0.00% 19:54 07/10 EDT
OPEN
0.5600
PREV CLOSE
0.5600
HIGH
0.5750
LOW
0.5460
VOLUME
3.60M
TURNOVER
--
52 WEEK HIGH
2.840
52 WEEK LOW
0.1027
MARKET CAP
95.72M
P/E (TTM)
-0.3724
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ONTX stock price target is 1.638 with a high estimate of 2.000 and a low estimate of 1.250.

EPS

ONTX News

More
Onconova Therapeutics Announces Publication of Phase 1 Results in Leukemia Research Exploring Oral Rigosertib in Combination with Azacitidine in Higher-Risk MDS
GlobeNewswire · 5d ago
Onconova Therapeutics Announces Phase 1 Results In Leukemia Research Exploring Oral Rigosertib In Combination With Azacitidine In Higher-Risk MDS
Onconova Therapeutics Announces Publication of Phase 1 Results in Leukemia Research Exploring Oral Rigosertib in Combination with Azacitidine in Higher-Risk MDS RAS-focused mechanism of action and manageable side effect
Benzinga · 5d ago
Onconova Initiates Phase I/IIa Study on Lung Cancer Candidate
Zacks · 06/23 15:43
Onconova Therapeutics Announces Participation in Noble Capital Markets Investor Webinar
GlobeNewswire · 06/23 13:00
Onconova Therapeutics Announces the Initiation of a Phase 1/2a Study of Rigosertib plus Nivolumab for the Treatment of KRAS+ Lung Adenocarcinoma
GlobeNewswire · 06/22 13:00
Onconova Therapeutics Announces Initiation Of A Phase 1/2a Study Of Rigosertib Plus Nivolumab For The Treatment Of KRAS+ Lung Adenocarcinoma
NEWTOWN, Pa., June 22, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial
Benzinga · 06/22 12:05
Onconova Therapeutics (ONTX) Investor Presentation - Slideshow
Seeking Alpha - Article · 06/12 18:47
Onconova Therapeutics shares are trading higher after the company highlighted its presentation at the European Hematology Association.
Benzinga · 06/12 15:01

Industry

Pharmaceuticals
-0.31%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About ONTX

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company's lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.
More

Webull offers kinds of Onconova Therapeutics Inc stock information, including NASDAQ:ONTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ONTX stock methods without spending real money on the virtual paper trading platform.